General Motors
BP
Ford Motor Company
AstraZeneca
DaimlerChrysler
CNN
General Electric
US Senate
Credit Suisse First Boston
Volkswagen
Siemens
Philip Morris
New York Life Insurance
Royal & SunAlliance
Bloomberg
Verizon
BP
Pfizer
AT&T
Macmillan Publishing
FIAT
Nestle
HP
General Dynamics
BP
Hewlett Packard
ABN Amro
UBS Warburg
Swiss Army
Merrill Lynch
AT&T
Nestle
Philips
New York Stock Exchange
AT&T
Nestle
The Economist
France Telecom
Boeing
Lafarge
Safeway
3
People's Republic of China's
Ministry of Agriculture
Nordea
Tesco
AstraZeneca
Pfizer
Philips
Credit Lyonnais
The Coca Cola Company
Ingersoll-Rand
Sybase
BBC
Sprint
New York Life Insurance
AstraZeneca
Canon USA
ABN Amro
Novell
Sun Microsystems
MOL
Ericsson
EDS
Philip Morris International
3
Royal & SunAlliance
Ericsson
Novartis
Credit Lyonnais
Danske Bank
Sun Microsystems
British American Tobacco
Norsk Hydro
US State Department
AstraZeneca
Skanska
BAE Systems
Ericsson
Kodak
The Royal Mail Group
Henkel
T-Mobile
Bank of Montreal
Danske Bank
BMW
Kronos Corporation
Fujitsu Technology Services
Lloyds
Zurich Financial Services
Halliburton
BBC
General Electric
Siemens
Philips
Blue Cross/Blue Shield of Massachusetts
Sun Microsystems
AstraZeneca
US Department of Defense
T-Mobile
Hewlett Packard
Channel 4 Corporation
UK Department of Trade & Industry
US Department of Defense
VHA
Burges Salmon
Motorola
British Telecom
Ferrari
Lloyds
Deloitte & Touche
PA Consulting
US Army
US State Department
UK Department of Trade & Industry
EMC Corporation
US Department of Commerce
Encana Corporation
IEEE
UK Department of Trade & Industry
Hewitt Associates LLC
HEALTHvision
Paramount
Lexmark
US Department of Defense
JD Edwards
Ingersoll-Rand
PricewaterhouseCoopers
Vodafone Omnitel
Nomura
Nestle
US State Department
Reed Elsevier
AstraZeneca
BBC
General Motors
Dow Chemical Company
Siemens Power Generation
Texas Instruments
Forrester Research
McData
Wall Street Journal
Lloyds
Philips
General Motors
NASA
SCA
Reuters
ITN
IBM NICA
Forbes.com
3
Nissan North America, Inc.
General Motors
Britvic Softdrinks
AstraZeneca
Toyota Motor
The McGraw-Hill Companies
Fox Sports
3
Society of Petroleum Engineers
US Department of Energy
European Commission
Telecom Italia
Harrah's
AXA
US Department of Commerce
Sybase
Napster
Oracle
Compuware
Olympus
ARM
Taylor & Francis
Federal Express
Nissan Motor
Milward Brown Precis
Federal Government of Canada
UK Home Office
Lloyds
3
HM Revenue & Customs
3
Harvard Business School
Britvic Softdrinks
MOL
Macmillan Publishing
Allianz Life Insurance Co
Henkel
Swiss Army
Vodafone Omnitel
Parliament of Singapore
VMS
Singapore Police Force
AstraZeneca
US State Department
Sony Music
Philips
GSA Advantage!
Kaiser Permanente
Sun Microsystems
The McGraw-Hill Companies
Stanford Business School
Johns Hopkins
Wachovia
Standard Life Insurance
Raytheon
Commerzbank
Allstate Insurance
State of Washington
Siemens
Napa Valley County
Texas Department of Transportation
BP
American HomePatient
TIBCO
Sharper Image
Xerox
America Online
3
Lockheed Northrop Grumman
Nestle
Hewlett Packard
Dow Chemical Company
General Motors
Draeger Medical
Sutter Health
Kenyan AIDS Clinic
HM Revenue & Customs
University of Washington
State of Minnesota
World Wildlife Fund
Autonomy Group Customers
 

Autonomy for Pharmaceuticals

Seven out of the 10 largest pharmaceutical companies in the world - from AstraZeneca and Pfizer to sanofi aventis - use Autonomy to increase R&D effectiveness and remain competitive in today's fast-paced scientific community. IDOL enables pharmaceutical companies to aggregate information from disconnected repositories, provide concept-based retrieval of in information in various formats, under the tightest security possible. With Autonomy, pharmaceutical researchers can eliminate costly duplication of life sciences research, leverage intellectual property, optimize product pipelines and shorten regulatory approval cycles.

Key Capabilities

Conceptual Retrieval
IDOL enables the extraction of meaning from the complex terminology prevalent in a pharmaceutical company's knowledge base of information, expertise and experience. IDOL understands the conceptual meanings of words rather than just matching keywords. For example, when a researcher does a search on amoxicillin, IDOL can bring up not just synonyms of the drug amoxicillin but also the family that amoxicillin belongs to, the beta-lactams.
Repository/Format Support
IDOL supports about 1,000 file formats, be it text, video or audio, and virtually every content repository including the document management systems most prevalent in the pharmaceutical industry such as OpenText, FileNet and Documentum.
Automatic Hyperlinking
IDOL automatically allows researchers and scientists to a range of pertinent documents, services and tools that are contextually linked to the original text. For example, a researcher searching on Pfizer's drug Viagra will be automatically linked to other content relating to Pfizer (eg. other drugs) or blindness (one of the supposed side effects of Viagra).
Automatic Query Guidance
One of the biggest challenges in the pharmaceutical world is that keyword searches bring back too many results that need to be sorted manually before they can be used. IDOL's Automatic Query Guidance technology automatically guides keyword-oriented users to the exact information they are looking for. A list of queries are presented to the user based on different contexts and the user can now guide the engine simply by clicking on the context that most applies to the subject they are researching. IDOL then automatically re-queries, adding this new-found context and, if required, suggests further sub-contexts within which the new query may be found. An example of this in the pharmaceutical world is the search for CAT. Automatic Query Guidance will bring up a list of queries such as CAT (feline); CAT (Caterpillar, Inc.), CAT (gene); CAT (Center for Alternate Technology), etc. The researcher can then use the CAT that is most suited to the initial search.
Clustering
IDOL Clustering organizes massive amounts of unstructured content into logical and easy to manage list of hot or breaking topics for scientists who may be looking for particular trends in their data such as the breakout of SARS in a new country or patients who are experiencing a side effect from using a particular drug.
Content Rationalization
IDOL automatically assists the rationalization of content to minimize the waste caused by the duplication of storage and effort. One of the core operations of IDOL is the ability to conceptually rate the similarity of two or more documents. Hence when content is created or indexed Autonomy automatically detects whether this specific piece of information already exists in the system and can trigger the appropriate action. What frequently occurs in the pharmaceutical industry is that scientists who cannot locate the experiment information they are looking for repeat the experiment. This is a significant productivity drain. In the pharmaceutical world, time to market is key. Even small gains of 1% or 2% translates into a drug appearing many weeks or even months ahead of traditional schedules. IDOL improves efficiency and reduces costs by its ability to detect whether a specific piece of information related to an experiment already exists in the system, helping eliminate costly duplication of research and giving pharmaceuticals that gain in time. In addition, IDOL helps pharmaceuticals with records retention, a huge challenge gripping this industry today.

Autonomy Pharmaceutical Case Studies

テクノロジー
機能
製品
ソリューション
サービス
導入実績
パートナーとOEM
ニュース & イベント
企業情報